A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B or
ipilimumab works compared with pembrolizumab in treating patients with stage III-IV melanoma
that has been removed by surgery but is likely to come back or spread. High-dose recombinant
interferon alfa-2B may help shrink or slow the growth of melanoma. Monoclonal antibodies,
such as ipilimumab and pembrolizumab, may block tumour growth in different ways by targeting
certain cells. It is not yet known whether high-dose recombinant interferon alfa-2B or
ipilimumab is more effective than pembrolizumab in treating patients with melanoma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society